ReviewTrends in molecular medicine2021
The gut microbiome as a biomarker of differential susceptibility to SARS-CoV-2.
Review in Trends in molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Human microbiota dysbiosis after SARS-CoV-2 infection have the potential to predict disease prognosis.BMC infectious diseases · 2023Pooled it
- Meta-analysis of 16S rRNA microbial data identified alterations of the gut microbiota in COVID-19 patients during the acute and recovery phases.BMC microbiology · 2022Pooled it
- Long COVID-19: The Need for an Interdisciplinary Approach.Clinics in geriatric medicine · 2022Pooled it
- Riboflavin Supplementation Promotes Butyrate Production in the Absence of Gross Compositional Changes in the Gut Microbiota.Antioxidants & redox signaling · 2023Trial
- Alterations of the gut commensalVirulence · 2025Article
- A specific microbial consortium enhances Th1 immunity, improves LCMV viral clearance but aggravates LCMV disease pathology in mice.Nature communications · 2025Article
- Nutraceuticals and pharmacological to balance the transitional microbiome to extend immunity during COVID-19 and other viral infections.Journal of translational medicine · 2024Review
- Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID.NPJ science of food · 2024Review
- Sex differences and individual variability in the captive Jamaican fruit bat (Artibeus jamaicensis) intestinal microbiome and metabolome.Scientific reports · 2024Article
- Review
- Gut microbiome and clinical and lifestyle host factors associated with recurrent positive RT-PCR for SARS-CoV-2.Frontiers in cellular and infection microbiology · 2024Article
- The role of gut microbiota in intestinal disease: from an oxidative stress perspective.Frontiers in microbiology · 2024Review
- Article
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study.Heliyon · 2023Article
- Gut microbiome alterations in patients with COVID-19-related coagulopathy.Annals of hematology · 2023Article
- Association of gut microbial dysbiosis with disease severity, response to therapy and disease outcomes in Indian patients with COVID-19.Gut pathogens · 2023Article
- Interferon-lambda: New role in intestinal symptoms of COVID-19.World journal of gastroenterology · 2023Review
- Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity.Microorganisms · 2023Review
- Gut microbiota and COVID-19: A systematic review.Health science reports · 2023Article
- COVID-19 host genetics and ABO blood group susceptibility.Cambridge prisms. Precision medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Coronavirus disease 2019 (COVID-19) continues to exact a devastating global toll. Ascertaining the factors underlying differential susceptibility and prognosis following viral exposure is critical to improving public health responses. We propose that gut microbes may contribute to variation in COVID-19 outcomes. We synthesise evidence for gut microbial contributions to immunity and inflammation, and associations with demographic factors affecting disease severity. We suggest mechanisms potentially underlying microbially mediated differential susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These include gut microbiome-mediated priming of host inflammatory responses and regulation of endocrine signalling, with consequences for the cellular features exploited by SARS-CoV-2 virions. We argue that considering gut microbiome-mediated mechanisms may offer a lens for appreciating differential susceptibility to SARS-CoV-2, potentially contributing to clinical and epidemiological approaches to understanding and managing COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.